Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 60

1.

A cervical empyema due to Panton-Valentine leukocidin Staphylococcus aureus.

Gazeau P, Jaffuel S, Garo B, Ansart S, Allano V.

Med Mal Infect. 2016 Apr 21. pii: S0399-077X(16)30005-1. doi: 10.1016/j.medmal.2016.03.007. [Epub ahead of print] No abstract available.

PMID:
27112520
2.

[Gemella haemolysans endocarditis in a patient with a bioprosthetic aortic valve].

Quaesaet L, Jaffuel S, Garo B, Tande D, Ansart S.

Med Mal Infect. 2016 Feb;46(1):61-3. doi: 10.1016/j.medmal.2015.11.011. Epub 2015 Dec 22. French. No abstract available.

PMID:
26725541
3.

Antibiotic use and good practice in 314 French hospitals: The 2010 SPA2 prevalence study.

Alfandari S, Robert J, Péan Y, Rabaud C, Bedos JP, Varon E, Lepape A, Bru JP, Gauzit R; French Infectious Diseases Society (French acronym SPILF), the French National Observatory for Epidemiology of Bacterial Resistance to Antibiotics (ONERBA), and the SPA2 group.

Med Mal Infect. 2015 Nov-Dec;45(11-12):475-80. doi: 10.1016/j.medmal.2015.10.001. Epub 2015 Nov 21.

PMID:
26612602
4.

Carbapenem use in French hospitals: A nationwide survey at the patient level.

Gauzit R, Pean Y, Alfandari S, Bru JP, Bedos JP, Rabaud C, Robert J; Société de Pathologie Infectieuse de Langue Française (SPILF); Observatoire National de l’Épidémiologie de la Résistance Bactérienne aux Antibiotiques (ONERBA); Surveillance de la Prescription des Antibiotiques (SPA) Group.

Int J Antimicrob Agents. 2015 Dec;46(6):707-12. doi: 10.1016/j.ijantimicag.2015.08.013. Epub 2015 Sep 30.

PMID:
26508585
5.

Update on a proper use of systemic fluoroquinolones in adult patients (ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin).

Chidiac C; SPILF working group.

Med Mal Infect. 2015 Sep;45(9):348-73. doi: 10.1016/j.medmal.2015.07.003. Epub 2015 Oct 1. No abstract available.

PMID:
26432627
6.

Escherichia coli bacteremia in children: age and portal of entry are the main predictors of severity.

Burdet C, Clermont O, Bonacorsi S, Laouénan C, Bingen E, Aujard Y, Mentré F, Lefort A, Denamur E; COLIBAFI Group.

Pediatr Infect Dis J. 2014 Aug;33(8):872-9. doi: 10.1097/INF.0000000000000309.

PMID:
25222308
7.

Escherichia coli bacteraemia in pregnant women is life-threatening for foetuses.

Surgers L, Bleibtreu A, Burdet C, Clermont O, Laouénan C, Lefort A, Mentré F, Carbonne B, Bingen E, Meynard JL, Denamur E; COLIBAFI Group.

Clin Microbiol Infect. 2014 Dec;20(12):O1035-41. doi: 10.1111/1469-0691.12742. Epub 2014 Aug 11.

8.

Escherichia coli bacteraemia in adults: age-related differences in clinical and bacteriological characteristics, and outcome.

Roubaud Baudron C, Panhard X, Clermont O, Mentré F, Fantin B, Denamur E, Lefort A; COLIBAFI Group.

Epidemiol Infect. 2014 Dec;142(12):2672-83. doi: 10.1017/S0950268814000211. Epub 2014 Feb 20.

PMID:
24559489
9.

Mupirocin/chlorexidine to prevent methicillin-resistant Staphylococcus aureus infections: post hoc analysis of a placebo-controlled, randomized trial using mupirocin/chlorhexidine and polymyxin/tobramycin for the prevention of acquired infections in intubated patients.

Camus C, Sebille V, Legras A, Garo B, Renault A, Le Corre P, Donnio PY, Gacouin A, Perrotin D, Le Tulzo Y, Bellissant E.

Infection. 2014 Jun;42(3):493-502. doi: 10.1007/s15010-013-0581-1. Epub 2014 Jan 25.

PMID:
24464791
10.

Complexity of Escherichia coli bacteremia pathophysiology evidenced by comparison of isolates from blood and portal of entry within single patients.

Clermont O, Glodt J, Burdet C, Pognard D, Lefort A, Branger C, Denamur E; COLIBAFI Group Members.

Int J Med Microbiol. 2013 Dec;303(8):529-32. doi: 10.1016/j.ijmm.2013.07.002. Epub 2013 Jul 17.

PMID:
23927963
11.

Implication of antibiotic referents in complex bone and joint infections.

Roger PM, Garo B, Roblot F, Bernard E.

Med Mal Infect. 2013 Apr;43(4):159-62. doi: 10.1016/j.medmal.2013.02.003. Epub 2013 Mar 6.

PMID:
23482061
12.

A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections.

Matthews P, Alpert M, Rahav G, Rill D, Zito E, Gardiner D, Pedersen R, Babinchak T, McGovern PC; Tigecycline 900 cSSSI Study Group.

BMC Infect Dis. 2012 Nov 12;12:297. doi: 10.1186/1471-2334-12-297.

13.

[Alliance against MDRO: safeguarding antibiotics].

Carlet J, Rambaud C, Pulcini C; l'Alliance contre développement des bactéries multirésistantes (ACdeBMR).

Ann Fr Anesth Reanim. 2012 Sep;31(9):704-8. doi: 10.1016/j.annfar.2012.07.003. Epub 2012 Aug 24. French.

PMID:
22925945
14.

[Stop bacterial resistance: save antibiotics].

Carlet J; le groupe Alliance francophone contre le développement des bactéries multi-résistantes aux antibiotiques (AC-2-BMR).

Med Mal Infect. 2011 Jul;41(7):351-2. doi: 10.1016/j.medmal.2011.06.003. Epub 2011 Jul 20. French. No abstract available.

PMID:
21764235
15.

[Soft tissue infection associated with bacteremia caused by Shewanella putrefaciens].

Rouzic N, Héry-Arnaud G, Jaffuel S, Garo B, Payan C, Garré M.

Pathol Biol (Paris). 2012 Jun;60(3):e27-9. doi: 10.1016/j.patbio.2011.04.005. Epub 2011 May 26. French.

PMID:
21616609
16.

[Epidemiology of healthcare-associated infections due to MRSA in Brest University Hospital from 2004 to 2007. Impact of hydroalcoholic gel and antibiotics consumptions].

Rouzic N, Tande D, Payan C, Garo B, Garre M, Lejeune B.

Pathol Biol (Paris). 2011 Feb;59(1):e1-5. doi: 10.1016/j.patbio.2010.10.001. Epub 2011 Feb 3. French.

PMID:
21295413
17.

Host factors and portal of entry outweigh bacterial determinants to predict the severity of Escherichia coli bacteremia.

Lefort A, Panhard X, Clermont O, Woerther PL, Branger C, Mentré F, Fantin B, Wolff M, Denamur E; COLIBAFI Group.

J Clin Microbiol. 2011 Mar;49(3):777-83. doi: 10.1128/JCM.01902-10. Epub 2010 Dec 22.

18.

Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features.

Courpon-Claudinon A, Lefort A, Panhard X, Clermont O, Dornic Q, Fantin B, Mentré F, Wolff M, Denamur E, Branger C; COLIBAFI Group.

Clin Microbiol Infect. 2011 Apr;17(4):557-65. doi: 10.1111/j.1469-0691.2010.03298.x.

19.

Recommendations for bone and joint prosthetic device infections in clinical practice (prosthesis, implants, osteosynthesis). Société de Pathologie Infectieuse de Langue Française.

Société de Pathologie Infectieuse de Langue Française (SPILF); Collège des Universitaires de Maladies Infectieuses et Tropicales (CMIT); Groupe de Pathologie Infectieuse Pédiatrique (GPIP); Société Française d'Anesthésie et de Réanimation (SFAR); Société Française de Chirurgie Orthopédique et Traumatologique (SOFCOT); Société Française d'Hygiène Hospitalière (SFHH); Société Française de Médecine Nucléaire (SFMN); Société Française de Médecine Physique et de Réadaptation (SOFMER); Société Française de Microbiologie (SFM); Société Française de Radiologie (SFR-Rad); Société Française de Rhumatologie (SFR-Rhu).

Med Mal Infect. 2010 Apr;40(4):185-211. doi: 10.1016/j.medmal.2009.12.009. Epub 2010 Mar 19. No abstract available.

PMID:
20303685
20.

Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database.

Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, Bienvenu B, Mouthon L, Guillevin L; French Vasculitis Study Group.

Arthritis Rheum. 2010 Feb;62(2):616-26. doi: 10.1002/art.27240.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk